---
title: "Dyne Therapeutics falls 6% during regular trading on earnings concerns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293483637.md"
description: "Dyne Therapeutics (DYN) fell 6% to $22.30 during regular trading as earnings-related pressure continued."
datetime: "2026-07-22T13:51:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293483637.md)
  - [en](https://longbridge.com/en/news/293483637.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293483637.md)
---

# Dyne Therapeutics falls 6% during regular trading on earnings concerns

Dyne Therapeutics(DYN.US) 盘中跌**6.42%**，现报**22.30**美元。

该股 5 分钟内急跌超 5%。消息面上，Dyne Therapeutics 盘前已因业绩相关因素承压，盘中继续急跌。

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Dyne Therapeutics director Dirk Kersten disposes of 261,460 common shares worth $6.67 million](https://longbridge.com/en/news/294254633.md)
- [Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News](https://longbridge.com/en/news/293794044.md)
- [Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway](https://longbridge.com/en/news/293529976.md)
- [Should FDA Priority Review of Dyne’s DMD Drug Candidate Reshape Risk Expectations for Dyne Therapeutics (DYN) Investors?](https://longbridge.com/en/news/293371591.md)
- [Dyne Therapeutics: Buy Rating Reiterated as FORCE Platform Expands; $47 Price Target Maintained](https://longbridge.com/en/news/294209392.md)